SAPU Bioscience Highlights Peer‑Reviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients

Core Insights - Sapu Biosciences, in collaboration with Oncotelic Therapeutics, has published new research indicating that TGFB2 expression and promoter methylation may serve as prognostic markers in pancreatic ductal adenocarcinoma (PDAC) [1][2] Group 1: Research Findings - The study published in the International Journal of Molecular Sciences highlights that targeting TGFB2 warrants further evaluation, particularly in younger PDAC patients [1][2] - Clinical data from the OT-101 P001 PDAC study shows that in a subset of younger patients with low IL-6, the median overall survival (OS) was 12.7 months [2] - High TGFB2 expression correlates with significantly reduced OS in patients under 65, with median OS of 17.9 months for high TGFB2 expression compared to 66.9 months for low [2] Group 2: Clinical Implications - Elevated TGFB2 methylation is associated with improved survival in younger patients, with median OS of 66.9 months for high methylation versus 17.9 months for low methylation [2] - The findings suggest that TGFB2 is not merely a biomarker but a critical factor delineating a younger subset of pancreatic cancer patients who experience poorer survival outcomes [2]